Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RXRX
)
3.170
-0.140 (-4.23%)
Streaming Delayed Price
Updated: 11:10 AM EDT, Jul 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
3 AI Stocks Disrupting Trillion-Dollar Industries
↗
September 02, 2025
These three companies are using artificial intelligence (AI) to transform defense, pharmaceuticals, and banking.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
↗
August 29, 2025
This AI company isn't yet living up to the hype.
Via
The Motley Fool
Topics
Artificial Intelligence
Recursion to Participate in Upcoming Investor Conferences
August 27, 2025
From
Recursion Pharmaceuticals
Via
GlobeNewswire
1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell
↗
August 25, 2025
There might be better artificial intelligence (AI) stocks out there to buy.
Via
The Motley Fool
Topics
Artificial Intelligence
Intellectual Property
Earnings Scheduled For August 5, 2025
↗
August 05, 2025
Via
Benzinga
Recursion Pharmaceuticals Earnings Preview
↗
August 04, 2025
Via
Benzinga
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
July 29, 2025
Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
August 27, 2025
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Emissions
The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode
↗
August 23, 2025
The artificial intelligence revolution is leaving no opportunity unaddressed.
Via
The Motley Fool
Topics
Artificial Intelligence
Why Recursion Pharmaceuticals Stock Caught a Cold This Week
↗
August 22, 2025
The few news items from and about the company weren't all that positive.
Via
The Motley Fool
Topics
Regulatory Compliance
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
August 12, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
↗
August 10, 2025
These companies are in the right place at the right time with the right products.
Via
The Motley Fool
Topics
Artificial Intelligence
Why Recursion Pharmaceuticals Stock Tanked on Tuesday
↗
August 05, 2025
It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.
Via
The Motley Fool
Recursion (RXRX) Q2 Revenue Jumps 33%
↗
August 05, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates
↗
August 05, 2025
Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per share,...
Via
Benzinga
Recursion Pharmaceuticals-A (NASDAQ:RXRX) Reports Mixed Q2 2025 Earnings: Revenue Beat but EPS Miss
↗
August 05, 2025
Recursion Pharmaceuticals (RXRX) reported mixed Q2 2025 results, beating revenue estimates with $19.22M but missing EPS at -$0.41. Shares rose 5.5% pre-market amid clinical progress and Sanofi...
Via
Chartmill
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
August 05, 2025
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7)
From
Recursion Pharmaceuticals
Via
GlobeNewswire
The Dawn of Hyper-Personalization: How Generative AI is Reshaping Our Digital World
August 04, 2025
The digital landscape is undergoing a profound transformation as personalized AI, particularly generative AI models, are increasingly being fine-tuned to individual preferences and histories. This...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
2 Beaten-Down Stocks With Incredible Upside Potential
↗
August 03, 2025
Getting in on the ground floor with these companies might lead to superior returns.
Via
The Motley Fool
Why Recursion Pharmaceuticals Stock Got Mashed on Monday
↗
July 28, 2025
Investors weren't cheered by news from one of the biotech's rivals.
Via
The Motley Fool
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
↗
July 26, 2025
You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.
Via
The Motley Fool
Topics
Artificial Intelligence
Retirement
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
↗
July 26, 2025
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
Via
Benzinga
Topics
Artificial Intelligence
ETFs
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma
↗
July 25, 2025
AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.
Via
Benzinga
3 AI Stocks Partnered With Nvidia With Massive Growth Opportunities
↗
July 23, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Biocomputers: The Future of Computing is Alive
July 22, 2025
In the rapidly evolving world of technology, a groundbreaking frontier is emerging that could redefine the very nature of computation: biocomputers. Unlike traditional computers built from...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Recursion Pharmaceuticals Sees Sharp Gain on AI Biotech Optimism
July 22, 2025
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) experienced a notable surge in its stock price as investor enthusiasm for artificial intelligence-driven biotechnology reached new highs. The rally comes...
Via
MarketMinute
Topics
Artificial Intelligence
Top 2 Health Care Stocks You May Want To Dump This Quarter
↗
July 22, 2025
Via
Benzinga
History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX)
July 21, 2025
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and...
Via
MarketMinute
Topics
Artificial Intelligence
Is Recursion Pharmaceuticals Gaining or Losing Market Support?
↗
July 21, 2025
Via
Benzinga
Why Is Recursion Pharma Stock Surging On Monday?
↗
July 21, 2025
Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
